Featured Article

International League Against Epilepsy Updates Epilepsy Classification System

International League Against Epilepsy Updates Epilepsy Classification System

The International League Against Epilepsy has revised its epilepsy classification system in an effort to inform epilepsy research and aid drug development.

Latest

Dose "Ceiling" May Exist for Epilepsy Treated With Lamotrigine

Dose "Ceiling" May Exist for Epilepsy Treated With Lamotrigine

A "ceiling" may exist for lamotrigine therapy above which remission from seizures may be unlikely.

FDA Approves Vagus Nerve Stimulator for Refractory Epilepsy

FDA Approves Vagus Nerve Stimulator for Refractory Epilepsy

The system includes a detect-and-respond mode, which is designed to prevent seizures before they start and deliver therapy to stop them if they do.

Epilepsy in the US: A Growing Public Health Concern

Epilepsy in the US: A Growing Public Health Concern

The CDC has updated the US national estimate of epilepsy prevalence and estimates 3.4 million people are affected by epilepsy.

Seizures More Likely in Patients With Sepsis Than General Population

Seizures More Likely in Patients With Sepsis Than General Population

Patients with sepsis included in this analysis may have presented with other CNS pathologies that could have contributed to seizure risk.

Antiepileptic Drugs Increase Risk of Birth Complications, Poor Fetal Health

Antiepileptic Drugs Increase Risk of Birth Complications, Poor Fetal Health

Pregnant women on antiepileptic drugs are at a higher risk of giving birth to a premature and SGA infant.

FDA Approves Expanded Seizure Indication for Aptiom

FDA Approves Expanded Seizure Indication for Aptiom

The FDA has approved an expanded indication for Aptiom to treat pediatric partial-onset seizures.

FDA Approves Briviact for Partial-Onset Seizure Monotherapy

FDA Approves Briviact for Partial-Onset Seizure Monotherapy

Briviact was initially approved as adjunct treatment for partial-onset seizures.

Buccal, Nasal Midazolam Most Cost-Effective for Pediatric Status Epilepticus

Buccal, Nasal Midazolam Most Cost-Effective for Pediatric Status Epilepticus

Rectal diazepam is currently the only FDA-approved treatment for pediatric status epilepticus.

Epilepsy Incidence Rates on the Rise in US Adults

Epilepsy Incidence Rates on the Rise in US Adults

Over 1% of the US population reported active or current epilepsy in 2015.

Cannabidiol May Impact Antiepileptic Drug Levels in Refractory Epilepsy

Cannabidiol May Impact Antiepileptic Drug Levels in Refractory Epilepsy

While several studies have demonstrated efficacy in refractory epilepsy, it is still not clear how cannabidiol may have an impact on current epilepsy treatments.

Sign Up for Free e-newsletters